The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unreponsive to standard heart failure therapyEijgenraam, T. R., Boukens, B. J., Boogerd, C. J., Schouten, E. M., van de Kolk, C. W. A., Stege, N. M., Te Rijdt, W. P., Hoorntje, E. T., van der Zwaag, P. A., van Rooij, E., van Tintelen, J. P., van den Berg, M. P., van der Meer, P., van der Velden, J., Silljé, H. H. W. & de Boer, R. A., 17-Jun-2020, In : Scientific Reports. 10, 1, 13 p., 9819.
Research output: Contribution to journal › Article › Academic › peer-review
Phospholamban (PLN) plays a role in cardiomyocyte calcium handling as primary inhibitor of sarco/endoplasmic reticulum Ca2+-ATPase (SERCA). The p.(Arg14del) pathogenic variant in the PLN gene results in a high risk of developing dilated or arrhythmogenic cardiomyopathy with heart failure. There is no established treatment other than standard heart failure therapy or heart transplantation. In this study, we generated a novel mouse model with the PLN-R14del pathogenic variant, performed detailed phenotyping, and tested the efficacy of established heart failure therapies eplerenone or metoprolol. Heterozygous PLN-R14del mice demonstrated increased susceptibility to ex vivo induced arrhythmias, and cardiomyopathy at 18 months of age, which was not accelerated by isoproterenol infusion. Homozygous PLN-R14del mice exhibited an accelerated phenotype including cardiac dilatation, contractile dysfunction, decreased ECG potentials, high susceptibility to ex vivo induced arrhythmias, myocardial fibrosis, PLN protein aggregation, and early mortality. Neither eplerenone nor metoprolol administration improved cardiac function or survival. In conclusion, our novel PLN-R14del mouse model exhibits most features of human disease. Administration of standard heart failure therapy did not rescue the phenotype, underscoring the need for better understanding of the pathophysiology of PLN-R14del-associated cardiomyopathy. This model provides a great opportunity to study the pathophysiology, and to screen for potential therapeutic treatments.
|Number of pages||13|
|Publication status||Published - 17-Jun-2020|
- CARDIAC-HYPERTROPHY, P.ARG14DEL MUTATION, ESC GUIDELINES, CARDIOMYOCYTES, PROTEASOME, GENE, DYSFUNCTION, INHIBITION, ACTIVATION, PROTECTS